Groowe Groowe / Newsroom / CHRS
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

CHRS News

Coherus Oncology, Inc. Common Stock

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

globenewswire.com
CHRS

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

globenewswire.com
FATE INDP AMGN NKTR IBIO TAK SNY INMB CLMT VERX GTBP BHVN CHRS GSK BMY MRK ABBV AZN GILD LLY KYMR REGN SPRY

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

globenewswire.com
CHRS

Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock

globenewswire.com
CHRS

TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight

prnewswire.com
RCUS GILD AZN CGEN CHRS

Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks

prnewswire.com
ONCY CHRS MRNA VIR MRK

Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape

prnewswire.com
GTBP IBRX ERAS CHRS NBP

The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

globenewswire.com
ONCY ALLO CHRS PYXS ELVN

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

globenewswire.com
CHRS

SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer

globenewswire.com
CHRS